Our results, therefore, suggest that CD25 could be a promising antigen for targeting LSC and immature AML cells alone or in combination with BCL-2 or FLT3 inhibitors in order to prevent relapse and disease progression. The gene discussed is FLT3; the disease is acute myeloid leukemia.